Cerebrospinal fluid-derived circulating tumor DNA is more comprehensive than plasma in NSCLC patients with leptomeningeal metastases regardless of extracranial evolution
Authors:
Open Access
- 15 December 2022
- Vol. 8 (12) , e12374
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81871865)
- Natural Science Foundation of Guangdong Province (2019A1515011943)
This publication has 16 references indexed in Scilit:
- Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisionsMolecular Oncology, 2019
- EGFR Amplification and Sensitizing Mutations Correlate with Survival in Lung Adenocarcinoma Patients Treated with Erlotinib (MutP-CLICaP)Targeted Oncology, 2018
- Non–small-cell Lung Cancer With Brain Metastasis at PresentationClinical Lung Cancer, 2018
- T-box 3 overexpression is associated with poor prognosis of non-small cell lung cancerOncology Letters, 2017
- Leptomeningeal Metastases in Patients with NSCLC with EGFR MutationsJournal of Thoracic Oncology, 2016
- Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasmaNature Communications, 2015
- PTEN and PI3K/AKT in Non-Small-Cell Lung CancerPharmacogenomics, 2015
- Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and ChemotherapyClinical Cancer Research, 2015
- Epidemiology of Brain MetastasesCurrent Oncology Reports, 2011
- Development of Central Nervous System Metastases in Patients with Advanced Non–Small Cell Lung Cancer and Somatic EGFR Mutations Treated with Gefitinib or ErlotinibClinical Cancer Research, 2010